Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
August 08, 2024 08:00 ET
|
Cassava Sciences, Inc.
$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for...
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
August 05, 2024 09:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson. We are profoundly saddened by the...
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
August 01, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...
Cassava Sciences Announces Expansion of Open-Label Extension Trials
July 30, 2024 08:15 ET
|
Cassava Sciences, Inc.
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on...
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024 08:00 ET
|
Cassava Sciences, Inc.
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 ...
Cassava Sciences Issues Statement on Former Science Advisor
June 28, 2024 15:58 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for...
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
May 10, 2024 16:02 ET
|
Cassava Sciences, Inc.
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3...
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
May 08, 2024 11:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of...
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
May 01, 2024 09:10 ET
|
Cassava Sciences, Inc.
End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of...
Redemption Date Announced for Warrants
April 15, 2024 09:20 ET
|
Cassava Sciences, Inc.
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences,...